Loading...
NPI 1902585680 · Torrance, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Biox Labs Inc is a clinical medical laboratory provider located in Torrance, California. This profile covers 1 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Biox Labs Inc |
| Address | 20695 S Western Ave Ste 136 |
| City | Torrance |
| State | CA |
| ZIP | 90501 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 11, 2023 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $10.6M |
| Medicaid | $15.1K |
BIOX LABS INC bills as a Clinical Medical Laboratory and its Medicare activity is almost exclusively driven by genomic sequencing for SARS–CoV–2: code 87913 (genotype analysis using next–generation sequencing) accounts for 41.9K claims, $252 avg paid/claim, and $10.5M revenue, which comprises the vast majority of the provider’s Medicare receipts within the Total Medicare revenue: $10.6M figure. This code-level mix indicates the organization operates as a specialized molecular/genomic testing lab with an operational focus on viral sequencing and variant identification rather than a broad clinical testing menu.
Revenue concentration is extreme: the precomputed top-3 Medicare CPT/HCPCS codes account for 100.0% of the provider’s Total Medicare revenue and the top-3 Medicaid codes account for 100.0% of the provider’s Total Medicaid revenue, signaling near-total dependence on a very narrow set of services for both payers. For practical analysis, this means payer negotiations, demand shifts, or reimbursement changes for 87913 could materially affect the entire revenue base.
Payer mix is effectively single-payer at scale: Total Medicare revenue: $10.6M dwarfs Total Medicaid revenue: $15.1K, so Medicare is the dominant commercial channel for this lab’s billed work while Medicaid activity is de minimis by comparison. Strategic or operational assessments should treat the provider as Medicare-centric for volume and financial exposure.
Competitive standing differs sharply by payer: for Medicare the provider ranks #1 of 11 nationally and sits at the 100th percentile for code 87913, described as notably above typical national volume, which positions BIOX LABS as a national-volume leader for SARS–CoV–2 genomic sequencing. In contrast, for Medicaid the provider also ranks #1 of 3 in-state for code 87913 but that activity is described as typical, unremarkable volume and represents only $15.3K and 372 claims, so the state-level Medicaid leadership does not reflect large absolute scale.
Payment pattern divergence between payers on the same code is notable: for 87913 Medicare shows $252 avg paid/claim while Medicaid shows $41 avg paid/claim for the identical code, suggesting substantial per-claim payment differentials between payers that materially affect revenue even when counts exist across both payers. Analysts should account for these per-claim rate differences when modeling revenue sensitivity to payer mix shifts.
Tenure and market entry: the provider’s NPI was enumerated on 2023-07-11 (~3 years ago), indicating a relatively recent enrollment date. Given the short apparent tenure and rapid accumulation of $10.6M in Medicare revenue concentrated in diagnostic sequencing, this pattern suggests a focused launch into high-volume genomic testing for SARS–CoV–2 rather than a long-established, diversified clinical laboratory.
Statistical outlier signal: the Medicare descriptor explicitly labels the provider’s 87913 activity as notably above typical national volume while the Medicaid descriptor characterizes in-state 87913 activity as typical, unremarkable volume. This dual signal implies that BIOX LABS is an outlier among national Medicare peers for high-volume sequencing but not an outlier within its smaller in-state Medicaid peer set, so peer comparisons and benchmarking should be conducted separately for each payer context.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 41,860 | $250 | $10.5M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87913 | 1 | 10 | 41,860 | $250 | $10.6M |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 370 | $40 | $15.3K |
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 1 | 10 | 360 | $30 | $9.8K |
Other providers in the same ZIP code as Biox Labs Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Byram Healthcare Centers, Inc. | CA | Pharmacy | $0 | $271.4M |
| Myt Home Health Care, LLC | CA | Durable Medical Equipment & Medical Supplies | $0 | $44.9M |
| Usa Biosciences LLC | CA | Clinical Medical Laboratory | $2.6M | $18.5M |
| Pacific Medical Labs | CA | Clinical Medical Laboratory | $7.3M | $16.1K |
| Imee Dhir | CA | Family Nurse Practitioner | $559K | $3.3K |
| Nicholas Fedor | CA | Physician Assistant | $12.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.